Full-length article|Articles in Press

T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma

Published:February 11, 2023DOI:


      B-cell maturation antigen (BCMA) is a clinically validated target for multiple myeloma. T-cell engineered with chimeric antigen receptors (CARs) directed against BCMA have demonstrated robust therapeutic activity in clinical trials, but toxicities remain a significant concern for a subset of patients, supporting continued investigation of other engineered T-cell platforms that may offer equal efficacy with an improved toxicity profile. The authors recently described a BCMA-specific, T-cell-centric synthetic antigen receptor, the T-cell antigen coupler (TAC) receptor, that can be used to engineer T-cell with robust anti-myeloma activity. Here the authors describe the creation of a fully humanized BCMA-specific TAC receptor. Single-chain variable fragments (scFvs) were developed from BCMA-specific F(ab)s that were identified in a fully human phage display library. Twenty-four configurations of the F(ab)s were evaluated in a medium-throughput screening using primary T-cell, and a single F(ab), TRAC 3625, emerged as the most robust following in vitro and in vivo evaluation. An optimized BCMA-specific TAC receptor was developed through iterations of the BCMA-TAC design that evaluated a next-generation TAC scaffold sequence, different domains connecting the TAC to the 3625 scFv and different orientations of the TRAC 3625 heavy and light variable regions.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Keller AL
        • Sherbenou DW
        • Forsberg PA
        • Mark TM.
        Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
        Front Oncol. 2022; 12925818
        • Mullard A.
        FDA approves second BCMA-targeted CAR-T cell therapy.
        Nat Rev Drug Discov. 2022; 21: 249
        • Carpenter RO
        • Evbuomwan MO
        • Pittaluga S
        • et al.
        B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
        Clin Cancer Res. 2013; 19: 2048-2060
      1. Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.

        • Drent E
        • Groen RW
        • Noort WA
        • et al.
        Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
        Haematologica. 2016; 101: 616-625
      2. Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood. 2017;130(26):2838-2847.

        • Tai YT
        • Acharya C
        • An G
        • et al.
        APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
        Blood. 2016; 127: 3225-3236
        • Raje N
        • Berdeja J
        • Lin Y
        • et al.
        Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
        N Engl J Med. 2019; 380: 1726-1737
        • Berdeja JG
        • Madduri D
        • Usmani SZ
        • et al.
        Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
        Lancet. 2021; 398: 314-324
        • Helsen CW
        • Hammill JA
        • Lau VWC
        • et al.
        The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity.
        Nat Commun. 2018; 9: 3049
        • Bezverbnaya K
        • Moogk D
        • Cummings D
        • et al.
        Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma.
        Cytotherapy. 2021; 23: 820-832
        • Nie Y
        • Lu W
        • Chen D
        • et al.
        Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies.
        Biomark Res. 2020; 8: 18
        • Turtle CJ
        • Hanafi LA
        • Berger C
        • et al.
        CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
        J Clin Invest. 2016; 126: 2123-2138
        • Maus MV
        • Haas AR
        • Beatty GL
        • et al.
        T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
        Cancer Immunol Res. 2013; 1: 26-31
        • Whitlow M
        • Bell BA
        • Feng SL
        • et al.
        An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.
        Protein Eng. 1993; 6: 989-995
        • Kuroda D
        • Shirai H
        • Jacobson MP
        • Nakamura H.
        Computer-aided antibody design.
        Protein Eng Des Sel. 2012; 25: 507-521
        • Arai R
        • Ueda H
        • Kitayama A
        • Kamiya N
        • Nagamune T.
        Design of the linkers which effectively separate domains of a bifunctional fusion protein.
        Protein Eng. 2001; 14: 529-532
        • Simms PE
        • Ellis TM.
        Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation.
        Clin Diagn Lab Immunol. 1996; 3: 301-304
      3. Helsen CW, Bramson J, Dvorkin-Gheva A, Denisova G, Bezverbnaya K, Mwawasi KA, inventors; McMaster University, assignee, T cell antigen coupler with Y177T mutation and methods of uses thereof. USA patent 11198737. 2021.

        • Otsuki T
        • Yamada O
        • Yata K
        • et al.
        Expression and production of interleukin 10 in human myeloma cell lines.
        Br J Haematol. 2000; 111: 835-842
        • Munshi NC
        • Anderson Jr., LD
        • Shah N
        • et al.
        Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
        N Engl J Med. 2021; 384: 705-716
        • Davis J
        • McGann M
        • Shockley A
        • Hashmi H.
        Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.
        Expert Rev Hematol. 2022; 15: 473-475
        • Martin T
        • Usmani SZ
        • Berdeja JG
        • et al.
        Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
        J Clin Oncol. 2022; JCO2200842
        • Husain B
        • Ellerman D.
        Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.
        BioDrugs. 2018; 32: 441-464
        • Park S
        • Shevlin E
        • Vedvyas Y
        • et al.
        Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.
        Sci Rep. 2017; 7: 14366
        • Liu X
        • Jiang S
        • Fang C
        • et al.
        Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.
        Cancer Res. 2015; 75: 3596-3607
        • Richman SA
        • Nunez-Cruz S
        • Moghimi B
        • et al.
        High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
        Cancer Immunol Res. 2018; 6: 36-46
      4. Ying Z, Huang XF, Xiang X, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947-953.

        • Shimabukuro-Vornhagen A
        • Gödel P
        • Subklewe M
        • et al.
        Cytokine release syndrome.
        J Immunother Cancer. 2018; 6: 56
        • Si S
        • Teachey DT.
        Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.
        Ther Clin Risk Manag. 2020; 16: 705-714
        • Zhang L
        • Wang S
        • Xu J
        • et al.
        Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy.
        Exp Hematol Oncol. 2021; 10: 16
        • Sterner RM
        • Sakemura R
        • Cox MJ
        • et al.
        GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
        Blood. 2019; 133: 697-709
        • Rabinovich BA
        • Ye Y
        • Etto T
        • et al.
        Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer.
        Proc Natl Acad Sci U S A. 2008; 105: 14342-14346
        • Persson H
        • Ye W
        • Wernimont A
        • et al.
        CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.
        J Mol Biol. 2013; 425: 803-811
        • Marqusee S
        • Baldwin RL
        Helix stabilization by Glu-...Lys+ salt bridges in short peptides of de novo design.
        Proc Natl Acad Sci U S A. 1987; 84: 8898-8902
        • Hammill JA
        • VanSeggelen H
        • Helsen CW
        • et al.
        Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors.
        J Immunother Cancer. 2015; 3: 55